Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 8/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.45 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | GRM8 | O00222 | 2/20 | 0.45 |
| ▸ | GRM6 | O15303 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28600615 | 1.00 | GRM4 (0.45) | GRM4CYP1A2GRM2GRM3CYP2C19 | |
| Bromide SCHEMBL9657131 | 0.97 | GRM4 (0.43) | GRM4CYP1A2GRM2GRM3CYP2C19 | |
| Hydrochloric Acid SCHEMBL2991552 | 0.97 | GRM4 (0.43) | GRM4CYP1A2GRM2GRM3CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL29456819 | 0.87 | GRM4 (0.37) | GRM4CYP1A2GRM2GRM3CYP2C19 | |
| SCHEMBL29956680 | 0.85 | — | — | |
| SCHEMBL1433577 | 0.85 | — | — | |
| SCHEMBL28595938 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL25279878 | 0.83 | GRM4 (0.41) | GRM4CYP1A2GRM2GRM3CYP2C19 | |
| Hydrochloric Acid SCHEMBL28913902 | 0.83 | GRM4 (0.41) | GRM4CYP1A2GRM2GRM3CYP2C19 | |
| Hydrochloric Acid SCHEMBL28913901 | 0.83 | GRM4 (0.41) | GRM4CYP1A2GRM2GRM3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1732 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | Technische Universität München (DE) | 2026-03-17 | — | — | US | claimed |
| EP-4696700-A1 | LONG-ACTING K-OPIOID RECEPTOR AGONIST | Chengdu Aoda Biotechnology Co., Ltd (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4696699-A1 | ? OPIOID RECEPTOR AGONIST AND USE THEREOF | Chengdu Aoda Biotechnology Co., Ltd. (CN) | 2026-02-18 | — | — | EP | claimed |
| US-12534498-B2 | Compounds for use as apelin receptor antagonists | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2026-01-27 | — | — | US | claimed |
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2026-01-01 | — | — | US | claimed |
| EP-4482578-B1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2025-12-24 | — | — | EP | claimed |
| US-12428447-B2 | Peptide-based non-proteinaceous cargo delivery | FELDAN BIO INC. (CA) | 2025-09-30 | — | — | US | claimed |
| EP-4619043-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | Perspective Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-0958305-B1 | INHIBITIONS OF THE INTERACTION BETWEEN P53 AND MDM2 | CANCER REC TECH LTD (GB) | 2008-06-04 | — | — | EP | claimed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | claimed |
| WO-2008033119-A1 | NOVEL COMBINATIONS OF DNAK INHIBITORS WITH KNOWN ANTIBACTERIAL AGENTS | CHAPERONE TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| US-7262163-B2 | Short amphipathic peptides with activity against bacteria and intracellular pathogens | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2007-08-28 | — | — | US | claimed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-20060287238-A1 | Novel combinations of DnaK inhibitors with known antibacterial agents | CHAPERONE TECHNOLOGIES, INC. | 2006-12-21 | — | — | US | claimed |
| US-20050137137-A1 | Inhibitors of the Interaction between p53 and MDM2 | LANE DAVID P (GB) | 2005-06-23 | — | — | US | claimed |
| US-20040059088-A1 | Short amphipathic peptides with activity against bacteria and intracellular pathogens | MCLAUGHLIN MARK L (US) | 2004-03-25 | — | — | US | claimed |
| US-6566334-B1 | For therapy of bacterial infection | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2003-05-20 | — | — | US | claimed |
| WO-1993000359-A1 | MODIFIED PEPTIDES TRANSPORTABLE INTO THE CENTRAL NERVOUS SYSTEM | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-01-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534498-B2 | Compounds for use as apelin receptor antagonists | APLNR, NPBWR1, AP3B1 | GRM4 675/4885CYP1A2 4661/4885GRM2 816/4885 |
| US-20060287238-A1 | Novel combinations of DnaK inhibitors with known antibacterial agents | DCK, DTYMK, POLK | GRM4 4715/4885CYP1A2 4762/4885GRM2 4672/4885 |
| US-20040059088-A1 | Short amphipathic peptides with activity against bacteria and intracellular pathogens | VIP, MDK, HM13 | GRM4 4379/4885CYP1A2 4880/4885GRM2 4555/4885 |
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | KLK3, FOLH1, SLC7A1 | GRM4 1780/4885CYP1A2 4726/4885GRM2 959/4885 |
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | GIPR, NPY2R, NPY1R | GRM4 63/4885CYP1A2 4024/4885GRM2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.